JEJoni K. Evans

Joni K. Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joni K. Evans has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Cody D. Blazek

    Wake Forest University School of Medicine, Assistant Professor - Department of Orthopaedic Surgery & Rehabilitation, Secondary Appointment Assistant Professor - Department of Vascular and Endovascular Surgery, Atrium Wake Forest Baptist Medical Center, Winston-Salem, NC

    5 shared publications
  • Aaron T. Scott

    Associate Professor, Department of Orthopaedic Surgery, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC

    2 shared publications
  • Courtney Bailey

    Division of Gynecological Oncology, Medical College of Georgia, Augusta, GA

    2 shared publications
  • David I. Shalowitz

    West Michigan Cancer Center, Kalamazoo, MI

    2 shared publications
  • Hayden L. Hoffler

    Fellow, Southeast Permanente Foot & Ankle Trauma & Reconstructive Fellowship Program, The Southeast Permanente Medical Group, Atlanta, GA

    2 shared publications
  • Jennifer A. Kipp

    Department of Orthopaedic Surgery and Rehabilitation, Atrium Health Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA

    2 shared publications

Latest Publications

  • Open Access

    Evaluation of closure materials on outcomes following transmetatarsal amputation: A retrospective review

    by Alec Wroblewski, Justin Waller, Joni K. Evans, Cody Blazek, John Bonvillian, Paula Gangopadhyay

  • Real-World Outcomes of Automated Insulin Delivery Use in Hospitalized Adults With Diabetes

    by Kathleen R. Ruddiman, Joni K. Evans, Joseph A. Aloi, Chinenye Usoh, Catherine Price

    Background: Automated insulin delivery (AID) systems are increasingly used by individuals living with diabetes in the outpatient setting, but data on their safety and effectiveness during hospitalizations remains limited. The objective is to evaluate the use and efficiency of AID systems in hospitalized adults with diabetes. Methods: We performed a retrospective cohort study based on electronic health record data from hospital admissions of 316 patients with diabetes using insulin pumps. Automated insulin delivery and continuous glucose monitor use, insulin pump continuation, length of stay (LOS), and glycemic outcomes among the cohort were analyzed. The primary aims of the study were to describe rates of insulin pump continuation and reasons associated with removal, and rates of pump reinitiation. Secondary outcomes included effects of insulin pump removal and prompt endocrinology consultation on inpatient glycemic outcomes and LOS. Results: Insulin pumps were continued in 64.2% of all admissions. The most common reason for pump discontinuation was surgery (30.1%). Length of stay was longer when pumps were removed (8.3 vs 4.7 days, P < .001) and when endocrinology consultation occurred more than 24 hours after admission ( P < .001). Insulin pump continuation was associated with lower hyperglycemia (glucose >180 mg/dL) rates without an increase in hypoglycemia (glucose <70 mg/dL) in both critical and noncritical care settings. Conclusions: Continuation of insulin pumps was associated with improvement in hyperglycemia without increased hypoglycemia risk and with shorter LOS in the hospital. Standardized institutional policies including prompt glycemic management team consultation may help expand safe continuation of AID during hospitalizations.

  • A Retrospective Cohort Study From 2 Academic Medical Centers: Oral vs Intravenous Antibiotics for Diabetic Osteomyelitis

    by Jennifer A. Kipp, Lindsay K. LeSavage, Joni K. Evans, Julia C. Tolin, Julianne Vesce, Travis Denmeade, Ricardo Arbulu, Jeffrey Manway, Cody D. Blazek

    Background: The Infectious Diseases Society of America guidelines recommend a prolonged course of antibiotics in the setting of residual osteomyelitis. More recently published literature suggests that oral antibiotics may offer comparable outcomes to intravenously administered antibiotics when treating orthopaedic infections. In a prior study, we investigated the outcomes of both routes of antibiotic administration in patients with diabetic foot infections at a single academic medical institution. Methods: The goal of this study is to retrospectively evaluate the therapeutic success in 196 patients receiving oral or intravenous antibiotics for treatment of residual infection following amputation at 2 academic medical centers. Treatment was considered successful if patients who completed a minimum of 4 weeks of antibiotic therapy had complete wound healing and did not require additional debridement or amputation within 1 year of their initial surgery. Results: After performing a retrospective chart review, no difference was determined in treatment success between patients who underwent oral or intravenous antibiotics at either WFBMC ( P = .34) or UPMC ( P = .99). No difference in success was found when combining institutional data ( P = .52). The median time to healing for oral antibiotics was 3.21 months compared with 3.85 months for intravenous ( P = .16). Reoperation rates did not differ among treatment types ( P = .53). Hemoglobin A 1c values were lower among patients with treatment success (8.6 ± 2.3) versus failure (9.5 ± 2.5) ( P = .016). Conclusion: This study supports the consideration of oral antibiotics as a viable option for selected diabetic patients with residual osteomyelitis. No significant differences were observed in treatment success, healing time, or reoperation rates, although the study was not powered to determine equivalence.


  • Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy

    by Alyssa A. Guo, Mary-Peyton Knapp, Joni K. Evans, Andrew T. Faucheux, Sarah N. Price, Heidi D. Klepin, Beverly Levine, Alexander Quattlebaum, Chance Bloomer, Lara Khoury, et al.

    Nearly half of patients with cancer are diagnosed at 70 years or older, which presents challenges in cancer care due to their high comorbidity burden and the underrepresentation of this age group in clinical trials. This retrospective study evaluated the association between comorbidity burden and immune checkpoint inhibitors (ICIs) treatment outcomes among older adults. Data were collected from patients aged 70 years or older at the time of diagnosis who were treated with ICIs from 2011 to 2022. Key clinical outcomes include changes in performance status, overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs) and were compared between low baseline Charlson Comorbidity Index (CCI) and high CCI (n = 300) had a significantly shorter OS (11.4 vs. 13.6 months, p = 0.0461) but similar PFS (8.0 vs. 7.7 months, p = 0.258) compared to patients with CCI scores p = 0.14) or in the irAE prevalence between the two groups (39.3% vs. 38.3%, p = 0.786). Our study suggests that ICIs are safe in patients with high comorbidity burden but that the presence of pre-treatment comorbidities decreases overall survival.


  • Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status

    by Safoa Addo, Thomas Lycan, David R. Soto-Pantoja, Yu-Ting Tsai, Ericson Stoen, Tamjeed Ahmed, Joni K. Evans, Lowell Hart, Jimmy Ruiz, Pierre Triozzi, et al.


  • Association between circulating ketone bodies and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA)

    by Parag Anilkumar Chevli, Alexander C. Razavi, Joni K. Evans, Richard Kazibwe, Margery A. Connelly, Sadiya S. Khan, Ambarish Pandey, Matthew C. Tattersall, James H. Stein, Michael D. Shapiro


  • Open Access

    The advantages of a dual incisional approach for talonavicular joint preparation: A cadaveric comparison study

    by Hayden L. Hoffler, Bryan Raymond, Bryanna D. Vesely, Joni K. Evans, Cody D. Blazek, Trevor E. Black

  • Multi-Institutional Study of Referral Patterns for Gynecologic Oncology Consultation

    by Joseph A. DeMari, Isheeta Madeka, Joni K. Evans, Courtney Bailey, Kristen Bartucci, Justin Bottsford-Miller, Leslie Bradford, Brian Burnett, Rebeca Kelly, Michelle Rowland, et al.

    PURPOSE Evaluation by a gynecologic oncologist (GO) is associated with improved clinical outcomes for patients with gynecologic cancers, yet little is known about health care factors that influence patients' referrals to GO. METHODS Medical records of 50 consecutive new patients seen in GO clinics at each of six referral centers across the United States were reviewed. Patient and disease characteristics were collected along with referral indication, evaluation and referral dates, diagnostic procedures, provider specialties, and zone improvement plan (ZIP) code of up to three referring providers per patient. The primary outcome was interval between first evaluation and referral. Univariate associations were evaluated with Chi-square and Wilcoxon rank-sum tests and multivariable associations with negative binomial regression models. Secondary outcome was prolonged time to GO referral, defined as greater than the 75th percentile. Logistic regression was used for multivariable modeling. RESULTS Three hundred patient records were analyzed. The median time from first health care encounter to referral was 15 days (IQR, 5-43). The mean distance from residence to GO was 39.8 miles (standard deviation, 53.8). Seventy-one percent of GO referrals were initiated by obstetrician-gynecologists, 9% by family physicians, and 6% internists. Presentation-to-referral interval was 76% shorter for patients evaluated by an emergency medicine clinician (exp(Beta), 0.24; 95% CI, 0.11 to 0.53; P < .001). Public insurance was associated with 1.47 times longer time to referral compared with private insurance (exp(Beta), 1.47; 95% CI, 1.05 to 2.04; P = .001). Residents of nonmetropolitan ZIP codes were less likely to have prolonged time to referral (odds ratio [OR], 0.288; P = .017). Distance from residence to GO (per 10 miles) increased the likelihood of prolonged time to referral (OR, 1.10; P = .010). CONCLUSION Interventions are needed to improve recognition and referral of patients for gynecologic oncology evaluation. Community outreach and engagement with obstetrician-gynecologists should be prioritized to improve times to referral.

  • Diabetic Osteomyelitis: Oral versus Intravenous Antibiotics at a Single Level 1 Academic Medical Trauma Center

    by Jennifer A. Kipp, Lindsay K. LeSavage, Joni K. Evans, Travis A. Denmeade, Cody D. Blazek


  • Open Access

    LONG-TERM ASSOCIATION OF AN INTENSIVE LIFESTYLE INTERVENTION ON FRAILTY AND MULTIMORBIDITY

    by Felicia Simpson, Mark Espeland, Joni Evans, Karen Johnson, Judy Bahnson, Denise Houston, Mia Yang, Lynne Wagenknecht

    Multidomain lifestyle interventions may slow aging as captured by deficit accumulation frailty indices (FIs) and multimorbidity. We previously reported that the 10-year Look AHEAD multidomain intensive lifestyle intervention (ILI) that focused on caloric restriction, increased physical activity, improved diet, and cardiometabolic risk factor monitoring, significantly slowed the progression of both FI and a multimorbidity index during intervention delivery. We assessed whether these benefits endured after ILI delivery was terminated and the degree to which these benefits may be interrelated. The Look AHEAD Aging study enrolled N=1606 individuals, ages 63-94 years, who had been assigned a median of 20 years earlier (i.e., 10 years after ILI was terminated) to either the Look AHEAD ILI or its control condition of diabetes support and education (DSE). At the original Look AHEAD randomization, they had a mean (SD) 39-component FI score of 0.128 (0.056) and mean (SD) 9-component multimorbidity index of 1.63 (1.01), both balanced across intervention groups. When enrolled in the Look AHEAD Aging study, participants who had been assigned to ILI, compared with those assigned to DSE, averaged 6% lower FI scores (p<0.0001). They had also accrued 0.14 fewer additional age-related chronic diseases from baseline (p<0.0001). Relative benefits associated with ILI for these indices were similar for both genders and across the full cohort’s age range. Increases in FI and multimorbidity were highly correlated (r=0.55; p<0.001), similarly in both arms. Multidomain lifestyle interventions can result in persistent long-term benefits in two common markers of aging.